LCRF-0004 is a potent and selective RON receptor tyrosine kinase inhibitor. The RON receptor tyrosine kinase has been identified as an important mediator of KRAS oncogene addiction and is overexpressed in the majority of pancreatic cancers. Preclinical studies show that inhibition of RON function decreases pancreatic cancer cell migration, invasion, and survival and can sensitize pancreatic cancer cells to chemotherapy. RON receptor tyrosine kinase is a potential as a therapeutic target. References: Raeppel F, Raeppel SL, Therrien E. Design, synthesis and RON receptor tyrosine kinase inhibitory activity of new head groups analogs of LCRF-0004. Bioorg Med Chem Lett. 2015 Jul 29. pii: S0960-894X(15)00784-2. doi: 10.1016/j.bmcl.2015.07.080. [Epub ahead of print] PubMed PMID: 26243370.

纯度：≥98%

CAS：1229611-73-7